美国泛发性脓疱型银屑病真实世界治疗模式:基于理赔数据的队列研究
本研究利用美国理赔数据库,在2015至2020年间识别出2630例泛发性脓疱型银屑病(GPP)患者,分为全GPP、GPP合并银屑病(PsO)、单纯GPP三个队列,分析诊断前后各365天的治疗模式;结果显示外用糖皮质激素是最常用治疗,系统性糖皮质激素使用比例较高,而单纯GPP患者接受生物制剂的比例低于GPP合并PsO患者。
要点
- 外用糖皮质激素是GPP诊断后最常处方的治疗。
- 系统性糖皮质激素使用比例高,尽管有停药后GPP flare的报道。
- 单纯GPP患者生物制剂使用率低于GPP合并PsO患者。
核心结论
- 糖皮质激素在GPP中被频繁处方,尽管已发表报告提示撤药后可能出现GPP flare。
- 单纯GPP患者接受生物制剂的比例低于GPP合并PsO患者,这与研究期间美国FDA缺乏获批的GPP靶向治疗一致。
研究设计与样本
- 基于理赔数据库的回顾性队列研究,数据时间为2015至2020年。
- 通过ICD-10编码识别3个队列:全GPP、GPP+PsO、单纯GPP,分析诊断后与诊断前各365天两个时期。
- 全GPP队列共2630例患者,其中单纯GPP 1246例,GPP+PsO 1384例。
主要发现
- 诊断后最常处方的治疗为外用糖皮质激素,其次为系统性糖皮质激素:GPP+PsO分别为55.7%和40.4%,单纯GPP分别为51.5%和42.0%。
- 诊断后GPP+PsO vs 单纯GPP:系统性生物制剂处方比例39.6% vs 21.5%,系统性非生物制剂36.9% vs 29.1%。
- 各队列中,诊断后系统性及外用糖皮质激素使用均低于诊断前,而其他治疗(外用维生素D衍生物、维A酸类、系统性生物制剂、系统性非生物制剂、光疗)使用高于诊断前。
临床怎么用
- 提示GPP临床治疗中糖皮质激素使用普遍,需关注撤药后flare风险。
- 提示单纯GPP患者生物制剂可及性可能不足,应结合指南与获批情况评估靶向治疗。
- 提示GPP与PsO在治疗模式上存在差异,临床管理需区分对待。
局限性
- 数据收集于美国FDA批准首个GPP生物制剂(spesolimab)之前。
- 研究为理赔数据库分析,治疗模式可能受编码与处方记录限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Generalized pustular psoriasis (GPP) is a chronic and life-threatening inflammatory skin disease, distinct from psoriasis (PsO). There is a lack of GPP treatment guidelines. OBJECTIVE: To characterize treatment patterns among patients with GPP in the US during two 365-day periods (postdiagnosis and prediagnosis) between 2015 and 2020. METHODS: Using a claims database, 3 cohorts were identified (All-GPP, GPP + PsO, GPP-only) from International Classification of Diseases, 10th revision codes. RESULTS: The study comprised of 2630 patients in the All-GPP cohort (n = 1246 GPP-only, n = 1384 GPP + PsO). Topical corticosteroids were the most frequently prescribed treatment postdiagnosis, followed by systemic corticosteroids: GPP + PsO (55.7% and 40.4%, respectively), GPP-only (51.5% and 42.0%). In the GPP + PsO vs GPP-only cohort, systemic biologics (39.6% vs 21.5%) and nonbiologics (36.9% vs 29.1%) were prescribed more frequently postdiagnosis. In each cohort, use of systemic and topical corticosteroids was lower postdiagnosis vs prediagnosis, whereas use of other therapeutics (topical vitamin D derivates, retinoids, systemic biologics, systemic nonbiologics, phototherapy) was higher. LIMITATIONS: Data collected before US Food and Drug Administration approval of the first biologic for GPP (spesolimab). CONCLUSIONS: Corticosteroids were frequently prescribed, despite published reports of GPP flare following withdrawal, and fewer GPP-only than GPP + PsO patients received biologics, consistent with the lack of US Food and Drug Administration-approved targeted therapies for GPP during the study.
引用
- Strober B, Kwiatkowski H, Lavasani L, et al. Real-world treatment patterns in patients with generalized pustular psoriasis: A US-based claims study. J Am Acad Dermatol. 2025. PMID: 40889717. doi:10.1016/j.jaad.2025.08.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。